Difference between revisions of "Goserelin (Zoladex)"
Jump to navigation
Jump to search
m (added package insert, links) |
m |
||
Line 32: | Line 32: | ||
[[Category:FDA approved in 1989]] | [[Category:FDA approved in 1989]] | ||
− |
Revision as of 15:08, 1 October 2019
General information
Class/mechanism: Gonadotropin-releasing hormone (GnRH) analog, inhibits pituitary gonadotropin secretion, which suppresses ovarian and testicular steroidogenesis[1][2]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Patient counseling information can be found in the package insert[1]
- Goserelin (Zoladex) patient drug information (Chemocare)[3]
- Goserelin (Zoladex) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 12/29/1989: Initial FDA approval (label not available on Drugs @ FDA)
Also known as
- Brand names: Novgos, Zoladex